Thymosin alpha 1 in the treatment of cancer: From basic research to clinical application

International Journal of Immunopharmacology

Volumn 22, Issue 12, 2000, Pages 1067-1076

  Garaci, Enrico ^a   Pica, Francesca ^a   Rasi, Guido ^a   Favalli, Cartesio ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Cancer; Immunotherapy; Thymosin alpha 1

Indexed keywords

INTERFERON; INTERLEUKIN 2; THYMOSIN ALPHA1;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RESEARCH; CYTOSTASIS; DRUG ACTIVITY; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; PRIORITY JOURNAL;

EID: 0034535749     PISSN: 01920561     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0192-0561(00)00075-8     Document Type: Short Survey

References (47)

1. Restorative effects of thymosin polypeptides on purified protein derivative-dependent migration inhibition factor production by peripheral blood lymphocytes of adult thymectomized guinea pigs
2. Comparative studies on the immunosuppressive effect among 5-deoxy-5-fluorouridine, ftorafur, and 5-fluorouracil
3. Thymosin a 1 exerts protective effect against the 5-FU induced bone-marrow toxicity
4. Production of human B and T cell growth factor is enhanced by thymic hormones
5. Thymosin treatment modulates production of interferon
6. Thymic hormonal activity on human peripheral blood lymphocytes, in vitro. II. Enhancement of the production of immune interferon by activated cells
7. Induction and augmentation of mitogen-induced immune interferon production in human peripheral blood lymphocytes by a-desacetyl thymosin α1
8. Modulation of interleukin 2 receptor expression on normal human lymphocytes thymic hormones
9. Characterization of the immunoregulatory properties of thymosin α1 on interleukin-2 production and interleukin-2 receptor expression in normal human lymphocytes
10. Thymosin alpha 1 modulates the expression of high affinity IL-2 receptors on normal human lymphocytes
11. Immunotherapy with natural interleukins and/or thymosin α1 potently augments T lymphocyte responses of hydrocortisone-treated aged mice
12. Thymosin-α1 stimulates maturation of CD34+ stem cells into CD3+4+ cellsin an in vitro thymic epithelia organ coculture model
13. Thymosin a 1. Isolation and sequence analysis of an immunologically active thymic polypeptide
14. Modulation of natural killer activity by thymosin alpha 1 and interferon
15. Modulation of human natural killer cell cytotoxic activity: Lymphokine production, and interleukin 2 receptor expression by thymic hormones
16. Enhanced immune response and antitumor immunity with combinations of biological response modifiers
17. Synergic effect of thymosin alpha 1 and alpha-beta interferon on NK activity in tumor-bearing mice
18. Rationale for therapeutic approaches with thymosin a 1, interleukin 2 and interferon in combination with chemotherapy
19. Combination treatment using thymosin a1 and interferon after cyclophosphamide is able to cure Lewis lung carcinoma in mice
20. Combination therapy with thymosin a1 potentiates the anti-tumor activity of interleukin-2 with cyclophosphamide in the treatment of the Lewis lung carcinoma in mice
21. Improved therapeutic effects of interleukin 2 after the accumulation of lymphokine-activated killer cells in tumor tissue of mice previously treated with cyclophosphamide
22. In vivo antitumor activity of multiple injections of recombinant interleukin-2, alone and in combination with three different types of recombinant interferon, on various syngenic murine tumors
23. Combination cytokine immunotherapy with tumor necrosis factor a, interleukin 2, and a-interferon and its synergistic antitumor effects in mice
24. Combined effects of chemotherapy and interleukin-2 in the therapy of mice with advanced pulmonary tumors
25. Immunotherapy of cancer using interleukin-2: Current status and future prospects
26. Tumour inhibition by interleukin-2 at tumour-host interface
27. Regression of established pulmonary metastases and sub-cutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin-2
28. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes
29. Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin-2
30. Lymphokine activated killer cell phenomenon. I. Lysis of natural killer-resistant fresh solid tumor cells by interleukin-2-activated autologous human peripheral blood lymphocytes
31. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2
32. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo
33. Thymosin a 1 potentiates interleukin 2-induced cytotoxic activity in mice
34. Antitumor effect of thymosin a1/Interleukin-2 or thymosin a1/Interfron a/b following cyclophosphamide in mice injected with highly metastatic Friend leukemia cells
35. Anti-tumor effect of combined treatment with thymosin alpha 1 and interleukin-2 after 5-fluorouracil in liver metastases from colorectal cancer in rats
36. High doses of thymosin alpha 1 enhance the anti-tumor efficacy of combination chemo-immunotherapy for murine B16 melanoma
37. The interferons. Mechanisms of action and clinical applications
38. Antineoplastic activity of the combination of interferon and cytotoxic agents in experimental and human malignancies: A review
39. Thymosin alpha 1 down-regulates the growth of human non-small cell lung cancer cells in vitro and in vivo
40. IFN-beta partially counteract inhibition of natural killer activity induced by some anti-tumor agents
41. HLA class I antigen down-regulation in human cancers: T-cell immunotherapy revives an old story
42. Thymosin-a1 regulates MHC class I expression in FRTL-5 cells at transcriptional level
43. IFN-a1 gene transfection completely abolishes the tumorigenicity of murine B16 melanoma cells in allogeneic DBA/2 mice and decreases their tumorigenicity in syngeneic C57BL/6 mice
44. Biochemotherapy with thymosin a1, interleukin-2 and dacarbazine in patients with metastatic melanoma: Clinical and immunological effects
45. Combined treatment with thymosin a1 and low-dose interferon-alpha after dacarbazine in advanced melanoma
46. Sequential chemoimmunotherapy for advanced non-small cell lung cancer using cisplatin, etoposide, thymosin-a1 and interferon-a2a
47. Combined treatment with thymosin-alpha 1 and low-dose interferon-alpha after ifosfamide in non-small cell lung cancer: A phase-II controlled trial